{"id":"W2556504054","doi":"10.1182/blood.v128.22.4144.4144","title":"Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Anaplastic large-cell lymphoma; Internal medicine; Oncology; Chemotherapy regimen; Peripheral T-cell lymphoma; Adverse effect; Progression-free survival; Lymphoma; Clinical endpoint; Phases of clinical research; Gastroenterology; Surgery; CD30; Chemotherapy; Clinical trial; Immunology; T cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003706286,0.0007113941,0.001234838,0.0002465157,0.0002916994,0.0006839813,0.0005031662,0.0006320414,0.001540708],"category_scores_gemma":[0.001564751,0.0002283298,0.001024664,0.0002784549,0.0003105667,0.0004827589,0.0003750253,0.001127207,0.0003694167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004559461,"about_ca_system_score_gemma":0.0004886821,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004209249,"about_ca_topic_score_gemma":0.0008963438,"domain_scores_codex":[0.9989772,0.000593378,0.00008051355,0.0001404843,0.0001161739,0.0000922692],"domain_scores_gemma":[0.998422,0.0004133933,0.0003755162,0.0001241116,0.000162905,0.0005020617],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6382311,0.01321041,0.1487129,0.001628101,0.006163764,0.0009734613,0.000574726,0.005171234,0.05370354,0.0002503707,0.009066625,0.1223138],"study_design_scores_gemma":[0.1914311,0.4033493,0.371976,0.0001638962,0.005356921,0.001732831,0.0001813485,0.003481434,0.008595527,0.0003250615,0.01331533,0.00009135395],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917526,0.004183423,0.0004264923,0.0001605982,0.00005135672,0.0004597238,0.00182573,0.00002386274,0.001116345],"genre_scores_gemma":[0.9919814,0.001283157,0.0003876967,0.000294845,0.00007373255,0.0003694817,0.004939239,0.000008829306,0.0006615135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003706286,"threshold_uncertainty_score":0.01960099,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01639331992627599,"score_gpt":0.2567977364663999,"score_spread":0.2404044165401239,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}